Tag: PACIFIC
No impact of grade ≥2 pneumonitis on patient-reported outcomes in PACIFIC

5-year PACIFIC data hold strong in NSCLC
Overcoming the challenges of immunotherapy in non–small cell lung cancer
Post-discontinuation immunotherapy in PACIFIC
Durvalumab after chemoradiotherapy extends OS in stage 3, unresectable non-small-cell lung cancer

Next generation immunotherapy in non-small-cell lung cancer
